

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 December 2021 (09.12.2021)



(10) International Publication Number
WO 2021/247779 A1

(51) International Patent Classification:

C07K 16/10 (2006.01) A61K 39/00 (2006.01)
A61K 39/215 (2006.01)

(21) International Application Number:

PCT/US2021/035556

(22) International Filing Date:

02 June 2021 (02.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/034,348	03 June 2020 (03.06.2020)	US
63/036,956	09 June 2020 (09.06.2020)	US
63/038,274	12 June 2020 (12.06.2020)	US
63/043,336	24 June 2020 (24.06.2020)	US
63/060,592	03 August 2020 (03.08.2020)	US
63/062,961	07 August 2020 (07.08.2020)	US
63/065,799	14 August 2020 (14.08.2020)	US
63/084,881	29 September 2020 (29.09.2020)	US
63/085,066	29 September 2020 (29.09.2020)	US
63/089,399	08 October 2020 (08.10.2020)	US
63/090,690	12 October 2020 (12.10.2020)	US
63/094,133	20 October 2020 (20.10.2020)	US
63/105,779	26 October 2020 (26.10.2020)	US
63/106,696	28 October 2020 (28.10.2020)	US
63/112,140	10 November 2020 (10.11.2020)	US
63/116,773	20 November 2020 (20.11.2020)	US
63/119,593	30 November 2020 (30.11.2020)	US
63/120,065	01 December 2020 (01.12.2020)	US
63/124,980	14 December 2020 (14.12.2020)	US
63/131,627	29 December 2020 (29.12.2020)	US
63/141,423	25 January 2021 (25.01.2021)	US
63/141,952	26 January 2021 (26.01.2021)	US
63/142,471	27 January 2021 (27.01.2021)	US
63/144,789	02 February 2021 (02.02.2021)	US
63/150,978	18 February 2021 (18.02.2021)	US
63/162,504	17 March 2021 (17.03.2021)	US
63/162,996	18 March 2021 (18.03.2021)	US
63/164,488	22 March 2021 (22.03.2021)	US
63/165,654	24 March 2021 (24.03.2021)	US
63/166,187	25 March 2021 (25.03.2021)	US
63/173,468	11 April 2021 (11.04.2021)	US
63/185,301	06 May 2021 (06.05.2021)	US
63/186,029	07 May 2021 (07.05.2021)	US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **GANGULY, Samit**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **HAMILTON, Jennifer**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **HERMAN, Gary**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **HOOPER, Andrea**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **ISA, Flonza**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **O'BRIEN, Meagan**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **SIVAPALASINGAM, Sumathi**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **TURNER, Kenneth**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **FORLEO NETO, Eduardo**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(74) Agent: **TERMES, Lance A.**; Schwabe, Williamson & Wyatt PC, 1211 SW 5th Ave., Suite 1900, Portland, Oregon 97204 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS FOR TREATING OR PREVENTING SARS-CoV-2 INFECTIONS AND COVID-19 WITH ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN ANTIBODIES

(57) Abstract: The present invention provides methods for preventing and treating SARS-CoV-2 infections, COVID-19, or symptoms thereof. The methods of the invention feature the administration of one or more antigen-binding molecules (e.g., antibodies) that bind a surface protein of SARS-CoV-2 (e.g., spike protein).



WO 2021/247779 A1

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*